Status:
TERMINATED
A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging
Lead Sponsor:
Forest Laboratories
Conditions:
Cardiovascular Disease
Ischemic Heart Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 w...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Have known or suspected heart disease
- Have undergone a clinically indicated SPECT MPI study with adenosine in the last 24 hours to 14 days.
- Weigh between 88 and 250 lbs.
Exclusion
- Allergic reaction to Technetium Tc99m Sestamibi or any of its components
- History of asthma or lung disease
- Ingestion of caffeinated substances within 12 hours prior to the study
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00162071
Start Date
July 1 2005
Last Update
February 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
New York, New York, United States, 10025